.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Healthtrust
UBS
Chubb
US Department of Justice
Fish and Richardson
Moodys
Federal Trade Commission
Fuji

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,012,469

« Back to Dashboard

Which drugs does patent 9,012,469 protect, and when does it expire?


Patent 9,012,469 protects MOVANTIK and is included in one NDA.

This patent has thirty-four patent family members in thirty-three countries.

Summary for Patent: 9,012,469

Title:Crystalline naloxol-peg conjugate
Abstract: Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Inventor(s): .ANG.slund; Bengt Leonard (Alderley Park, GB), Aurell; Carl-Johan (Alderley Park, GB), Bohlin; Martin Hans (Alderley Park, GB), Healy; Eric Thomas (Waltham, MA), Jensen; David Richard (Waltham, MA), Jonaitis; David Thomas (Waltham, MA), Parent; Stephan (Waltham, MA), Sebhatu; Tesfai (Alderley Park, GB), Ymen; Bo Ingvar (Alderley Park, GB)
Assignee: AstraZeneca AB (Sodertalje, SE) Nektar Therapeutics (San Francisco, CA)
Application Number:13/823,953
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo9,012,469► SubscribeYY
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes9,012,469► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,012,469

PCT Information
PCT FiledSeptember 29, 2011PCT Application Number:PCT/SE2011/051161
PCT Publication Date:April 05, 2012PCT Publication Number: WO2012/044243

Non-Orange Book Patents for Patent: 9,012,469

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,149,539Crystalline naloxol-PEG conjugate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,012,469

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office2621496► Subscribe
European Patent Office2992903► Subscribe
Spain2562643► Subscribe
Guatemala201300084► Subscribe
Hong Kong1187248► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Covington
Merck
Argus Health
Farmers Insurance
Daiichi Sankyo
Moodys
US Army
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot